NEUROPATHOLOGY CORE

神经病理学核心中心的主要目标是促进和支持轻度认知障碍(MCI)、阿尔茨海默病和其他神经退行性疾病的研究，方法是储存和分配具有良好特征的组织，并对即将进行尸检的ADC登记病例进行全面的神经病理学评估。为了更好地实现这一目标，埃默里ADC将与印第安纳大学ADC的神经病理核心合作。这两个机构的资源组合及其独特优势创造了一种协同关系，这种关系将建立在现有机构间的基础上 (1)对痴呆症患者、对照组和轻度认知障碍受试者的尸检脑进行全面的神经病理、生化和分子遗传学评估。这项评估包括表征AD和与其他神经疾病(例如帕金森氏病和路易体痴呆、额颞痴呆和血管疾病)相关的痴呆的异质性。(2)生成可靠的神经病理数据，以便与临床核心收集的信息相关联，并用于Emory的研究研究 大学、印第安纳大学和其他机构。(3)维持一个活跃的组织库，以促进采集、储存、处理和分发具有良好特征的尸检脑组织、DMA和其他生物样本。(4)对临床核心获取的所有血液样本和神经病理学核心获取的所有尸检病例的载脂蛋白E基因进行测定，对与神经退行性疾病相关的其他基因进行分子遗传分析，并促进使用 神经病理学核心的DNA提取物库，血浆样本，以及在基因分型过程中产生的棕黄色外套分离物。

The primary goal of the Neuropathology Core is to promote and support research on mild cognitive impairment (MCI), Alzheimer's disease and other neurodegenerative disorders through banking and distribution of well-characterized tissue coupled with comprehensive neuropathologic assessment of ADC registry cases coming to autopsy. To best achieve this goal, the Emory ADC will work in partnership with the Neuropathology Core of the Indiana University ADC. The combined resources of the two institutions and their unique strengths create a synergistic relationship that will build upon already existing inter-institutional collaborations, enhance the capabilities of both institutions, and support the achievement of the primary goal of the Neuropathology Core through the following activities: (1) Comprehensive neuropathologic, biochemical and molecular genetic assessment of autopsy brains from dementia patients, controls and subjects with mild cognitive impairment. This assessment includes characterization of the heterogeneity of AD and dementias associated with other neurologic disorders (e.g., Parkinson's disease and Lewy body dementia, frontotemporal dementias, and vascular disease). (2) Generation of reliable neuropathologic data for correlation with information collected by the Clinical Core and for use in research studies at Emory University, Indiana University, and other institutions. (3) Maintenance of an active tissue bank to facilitate the acquisition, storage, handling, and distribution of well-characterized autopsy brain tissue, DMA, and other biological samples. (4) Determination of ApoE genotype on all blood samples accessioned by the Clinical Core and on all autopsy cases accessioned by the Neuropathology Core, molecular genetic analysis of other genes associated with neurodegenerative disease, and facilitation of collaborative investigations using the Neuropathology Core's bank of DNA extracts, plasma samples, and buffy coat isolates generated during the genotyping process.